Goldman Sachs Group Inc Supernus Pharmaceuticals, Inc. Transaction History
Goldman Sachs Group Inc
- $706 Billion
- Q2 2025
A detailed history of Goldman Sachs Group Inc transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 896,387 shares of SUPN stock, worth $46.2 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
896,387
Previous 824,155
8.76%
Holding current value
$46.2 Million
Previous $27 Million
4.68%
% of portfolio
0.0%
Previous 0.0%
Shares
22 transactions
Others Institutions Holding SUPN
# of Institutions
313Shares Held
61.5MCall Options Held
18.4KPut Options Held
0-
Black Rock Inc. New York, NY10.4MShares$536 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.21MShares$320 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY4.81MShares$248 Million2.66% of portfolio
-
Dimensional Fund Advisors LP Austin, TX3.02MShares$156 Million0.02% of portfolio
-
Macquarie Group LTD Australia, C32.76MShares$142 Million0.11% of portfolio
About SUPERNUS PHARMACEUTICALS, INC.
- Ticker SUPN
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 53,495,300
- Market Cap $2.76B
- Description
- Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...